Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome injection into cesarean scar during third cesarean section
IRCT20091012002576N45Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of endothelial progenitor cell-derived exosomes in Caesarean scar defect (CSD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Niche size based on transvaginal sonogram. Started Sep 2024; status: completed.
02
Drugs
endothelial progenitor cell-derived exosomes
03
Conditions
Caesarean scar defect (CSD)
Beyond the preview
Go deeper on IRCT20091012002576N45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002576N45.